Hematopoietic Stem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousTransplantation ChimeraBone MarrowTissue DonorsGraft vs Leukemia EffectWhole-Body IrradiationBone Marrow CellsPeripheral Blood Stem Cell TransplantationBusulfanLeukemiaHistocompatibilityTreatment OutcomeHistocompatibility TestingGraft SurvivalRecurrenceMyeloablative AgonistsGraft vs Tumor EffectRetrospective StudiesChimerismHematologic DiseasesLeukemia, Myeloid, AcuteStem CellsAnemia, AplasticMyelodysplastic SyndromesImmunosuppressive AgentsVidarabineRemission InductionCord Blood Stem Cell TransplantationLymphocyte TransfusionHLA AntigensPrecursor Cell Lymphoblastic Leukemia-LymphomaHepatic Veno-Occlusive DiseaseAllograftsTransplantation, IsogeneicLiver TransplantationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSiblingsCombined Modality TherapyTime FactorsHematopoiesisTransplantation ImmunologySurvival RateCytomegalovirus InfectionsSurvival AnalysisAcute DiseaseCyclophosphamideLymphocyte DepletionT-LymphocytesDisease-Free SurvivalMice, Inbred C57BLSevere Combined ImmunodeficiencyFollow-Up StudiesMultiple MyelomaOpportunistic InfectionsFlow CytometryCystitisMinor Histocompatibility AntigensLeukemic InfiltrationHematopoietic Stem Cell MobilizationAntigens, CD34Leukemia, MyeloidImmunosuppressionNeoplasm, ResidualKidney TransplantationAntilymphocyte SerumSalvage TherapyLymphoproliferative DisordersCell DifferentiationBone and BonesGraft RejectionAntineoplastic Combined Chemotherapy ProtocolsCytomegalovirusImmunocompromised HostPrognosisBlood Group IncompatibilityFatal OutcomeBronchiolitis ObliteransRisk FactorsCyclosporineBone Marrow PurgingCytarabineColony-Forming Units AssayCell TransplantationMelphalanMesenchymal Stem Cell TransplantationMycosesCell LineagePrimary MyelofibrosisLymphoma, Non-HodgkinRadiation ChimeraCells, CulturedGanciclovir